Trial Profile
A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs BCT 100 (Primary)
- Indications Acute myeloid leukaemia; Glioma; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PARC
- 01 Sep 2022 Status changed from active, no longer recruiting to completed.
- 05 Jun 2022 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 02 Dec 2020 Planned End Date changed from 16 Oct 2021 to 16 Oct 2022.